Balance Sheet Eisai Co., Ltd.

Stocks

4523

JP3160400002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:30:21 15/06/2026 am IST			5-day change	1st Jan Change
3,829.00 ^JPY	+1.30%		+0.60%	-17.83%

07:08am	UK, Japan Enter Into GBP 18 Billion Deal to Boost Clean Energy, Jobs, Next-Generation Tech	MT
11/06	Beren Therapeutics P.B.C. announced that it has received $245 million in funding from Eisai Co., Ltd., The Founders Fund, LLC, Wellington Partners Advisory AG, Narya Capital, JIC Venture Growth Investments Co., Ltd. and other investors	CI

b01d57ae8bcea89b724be753f23cf5a.vv2qFSSrLwlSqrEUikuDrHouSJJvNc315rCWoI6Xz88.iYr9U0LpGk8684Qh5h3l2gAeIscuY7u9jNOv-eb8tZ__v-dTdvthazzS2g

Published financial data: EISAI CO., LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	65TCr	76TCr	74TCr	74TCr	79TCr
Total Revenues	65TCr	76TCr	74TCr	74TCr	79TCr
Cost of Goods Sold, Total	16TCr	17TCr	18TCr	16TCr	17TCr
Gross Profit	48TCr	58TCr	57TCr	59TCr	62TCr
Selling General & Admin Expenses, Total	27TCr	36TCr	35TCr	36TCr	40TCr
R&D Expenses	15TCr	17TCr	17TCr	17TCr	17TCr
Depreciation & Amortization - (IS)	882.8Cr	958.3Cr	1.02TCr	1.03TCr	1.14TCr
Other Operating Expenses	-28Cr	79Cr	-316.1Cr	-110.9Cr	-609.4Cr
Other Operating Expenses, Total	43TCr	54TCr	53TCr	54TCr	57TCr
Operating Income	5.32TCr	4.24TCr	3.84TCr	4.41TCr	4.71TCr
Interest Expense, Total	-116Cr	-142.9Cr	-165.8Cr	-188.4Cr	-275.5Cr
Interest And Investment Income	195.8Cr	220.9Cr	509.3Cr	1.01TCr	1.01TCr
Net Interest Expenses	80Cr	78Cr	343.5Cr	819.3Cr	731Cr
Income (Loss) On Equity Invest.	-	-	-	-	-
Currency Exchange Gains (Loss)	-145.3Cr	-208.3Cr	-219.9Cr	46Cr	-240.8Cr
Other Non Operating Income (Expenses)	-7.2Cr	-6.2Cr	-6Cr	-6.3Cr	-6.3Cr
EBT, Excl. Unusual Items	5.25TCr	4.11TCr	3.96TCr	5.27TCr	5.19TCr
Impairment of Goodwill	-	-	-	-	-
Gain (Loss) On Sale Of Investments	5.9Cr	-1Cr	540.1Cr	28Cr	-56Cr
Gain (Loss) On Sale Of Assets	-	1.34TCr	-	885.9Cr	971.4Cr
EBT, Incl. Unusual Items	5.26TCr	5.45TCr	4.5TCr	6.18TCr	6.11TCr
Income Tax Expense	1.01TCr	874.1Cr	-1.18TCr	1.8TCr	1.3TCr
Earnings From Continuing Operations	4.25TCr	4.57TCr	5.68TCr	4.38TCr	4.81TCr
Net Income to Company	4.25TCr	4.57TCr	5.68TCr	4.38TCr	4.81TCr
Minority Interest	-36Cr	223.7Cr	-140.4Cr	-137.7Cr	-162.6Cr
Net Income - (IS)	4.21TCr	4.8TCr	5.54TCr	4.24TCr	4.64TCr
Net Income to Common Incl Extra Items	4.21TCr	4.8TCr	5.54TCr	4.24TCr	4.64TCr
Net Income to Common Excl. Extra Items	4.21TCr	4.8TCr	5.54TCr	4.24TCr	4.64TCr
Per Share Items
Net EPS - Basic	146.95	167.27	193.31	147.86	163.76
Basic EPS - Continuing Operations	146.95	167.27	193.31	147.86	163.76
Basic Weighted Average Shares Outstanding	29Cr	29Cr	29Cr	29Cr	28Cr
Net EPS - Diluted	146.9	167.25	193.31	147.86	163.76
Diluted EPS - Continuing Operations	146.9	167.25	193.31	147.86	163.76
Diluted Weighted Average Shares Outstanding	29Cr	29Cr	29Cr	29Cr	28Cr
Normalized Basic EPS	113.2	97.34	81.44	110	108.69
Normalized Diluted EPS	113.16	97.32	81.44	110	108.69
Dividend Per Share	160	160	160	160	160
Payout Ratio	108.9	95.67	82.79	108.27	98.09
American Depositary Receipts Ratio (ADR)	0.25	0.25	0.25	0.25	0.25
Supplemental Items
EBITDA	8.95TCr	8.08TCr	7.84TCr	8.35TCr	8.7TCr
EBITA	5.32TCr	4.24TCr	3.84TCr	4.41TCr	4.71TCr
EBIT	5.32TCr	4.24TCr	3.84TCr	4.41TCr	4.71TCr
Effective Tax Rate - (Ratio)	19.16	16.05	-26.27	29.18	21.3
Normalized Net Income	3.24TCr	2.79TCr	2.34TCr	3.15TCr	3.08TCr
Non-Cash Pension Expense	-4.5Cr	-8.9Cr	-8.9Cr	-39Cr	-29Cr
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	15TCr	17TCr	17TCr	17TCr	17TCr

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	25TCr	31TCr	27TCr	30TCr	27TCr
Total Cash And Short Term Investments	25TCr	31TCr	27TCr	30TCr	27TCr
Accounts Receivable, Total	16TCr	21TCr	19TCr	22TCr	22TCr
Total Receivables	16TCr	21TCr	19TCr	22TCr	22TCr
Inventory	8.51TCr	9.9TCr	14TCr	17TCr	22TCr
Other Current Assets, Total	2.42TCr	2.4TCr	2.72TCr	2.64TCr	2.62TCr
Total Current Assets	52TCr	64TCr	62TCr	72TCr	73TCr
Net Property Plant And Equipment	16TCr	17TCr	17TCr	16TCr	16TCr
Long-term Investments	6.34TCr	6.5TCr	7.39TCr	8.32TCr	9.08TCr
Goodwill	17TCr	19TCr	21TCr	24TCr	23TCr
Other Intangibles, Total	11TCr	9.55TCr	8.92TCr	8.55TCr	7.53TCr
Deferred Tax Assets Long-Term	6.69TCr	7.66TCr	10TCr	10TCr	10TCr
Other Long-Term Assets, Total	10L	-	10L	-10L	-
Total Assets	1,09000Cr	1,23900Cr	1,26300Cr	1,39400Cr	1,38700Cr
Liabilities
Accounts Payable, Total	9.45TCr	11TCr	8.68TCr	7.22TCr	9.16TCr
Short-term Borrowings	-	-	3.12TCr	2.46TCr	5.27TCr
Current Portion of Long-Term Debt	4TCr	-	1TCr	-	3.5TCr
Current Income Taxes Payable	252.2Cr	687.7Cr	222.3Cr	871.8Cr	426Cr
Other Current Liabilities	12TCr	20TCr	17TCr	20TCr	19TCr
Total Current Liabilities	26TCr	31TCr	30TCr	30TCr	37TCr
Long-Term Debt	4.99TCr	9.49TCr	8.49TCr	13TCr	9.98TCr
Pension & Other Post Retirement Benefits	877.8Cr	1.08TCr	1.11TCr	685.2Cr	485.1Cr
Deferred Tax Liability Non Current	51Cr	48Cr	66Cr	70Cr	73Cr
Other Non Current Liabilities	4.69TCr	4.82TCr	4.52TCr	4.8TCr	4.29TCr
Total Liabilities	36TCr	47TCr	44TCr	49TCr	52TCr
Common Stock, Total	4.5TCr	4.5TCr	4.5TCr	4.5TCr	4.5TCr
Additional Paid In Capital	7.76TCr	7.76TCr	7.88TCr	7.89TCr	7.48TCr
Retained Earnings	51TCr	51TCr	52TCr	53TCr	51TCr
Treasury Stock	-3.4TCr	-3.39TCr	-3.36TCr	-3.36TCr	-4.23TCr
Comprehensive Income and Other	11TCr	15TCr	19TCr	26TCr	25TCr
Total Common Equity	70TCr	75TCr	80TCr	88TCr	84TCr
Minority Interest	2.48TCr	2.27TCr	2.26TCr	2.34TCr	2.46TCr
Total Equity	73TCr	77TCr	82TCr	90TCr	87TCr
Total Liabilities And Equity	1,09000Cr	1,23900Cr	1,26300Cr	1,39400Cr	1,38700Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	29Cr	29Cr	29Cr	29Cr	28Cr
ECS Total Common Shares Outstanding	29Cr	29Cr	29Cr	29Cr	28Cr
Book Value / Share	2.45T	2.61T	2.79T	3.05T	2.98T
Tangible Book Value	42TCr	46TCr	50TCr	55TCr	53TCr
Tangible Book Value Per Share	1.47T	1.61T	1.75T	1.93T	1.89T
Total Debt	8.99TCr	9.49TCr	13TCr	16TCr	19TCr
Net Debt	-16TCr	-21TCr	-14TCr	-15TCr	-7.8TCr
Debt Equivalent of Unfunded Proj. Benefit Obligation	-666.5Cr	-657.8Cr	-778.4Cr	-2.2TCr	-2.82TCr
Minority Interest, Total (Incl. Fin. Div)	2.48TCr	2.27TCr	2.26TCr	2.34TCr	2.46TCr
Inventories - Raw Materials, Total	2.18TCr	2.82TCr	6.71TCr	8.69TCr	12TCr
Inventories - Work In Process, Total	2.18TCr	2.54TCr	2.56TCr	3.86TCr	3.9TCr
Inventories - Finished Goods, Total	4.15TCr	4.53TCr	4.77TCr	4.91TCr	5.56TCr
Inventories - Others	-	-	-10L	-	-
Full Time Employees	11.24T	11.32T	11.08T	11.07T	10.92T
Accumulated Allowance for Doubtful Accounts (Supple)	34Cr	58Cr	70Cr	78Cr	69Cr

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	5.26TCr	5.45TCr	4.5TCr	6.18TCr	6.11TCr
Depreciation & Amortization - CF	3.63TCr	3.84TCr	4TCr	3.94TCr	3.99TCr
Depreciation & Amortization, Total	3.63TCr	3.84TCr	4TCr	3.94TCr	3.99TCr
(Gain) Loss From Sale Of Asset	21Cr	1.14TCr	201.9Cr	239.8Cr	429Cr
Other Operating Activities, Total	-1.55TCr	-2.08TCr	-2.73TCr	-2.04TCr	-2.78TCr
Change In Accounts Receivable	2.56TCr	-4.01TCr	3.74TCr	149.6Cr	-1.72TCr
Change In Inventories	-1.4TCr	-633.7Cr	-3.69TCr	-2.17TCr	-4.4TCr
Change In Accounts Payable	-136.7Cr	103.3Cr	457.1Cr	-1.11TCr	1.35TCr
Change in Other Net Operating Assets	-1TCr	7.96TCr	-6.66TCr	404Cr	35Cr
Cash from Operations	7.39TCr	12TCr	-177.2Cr	5.6TCr	3.01TCr
Capital Expenditure	-1.91TCr	-2.9TCr	-2.26TCr	-1.43TCr	-1.19TCr
Sale of Property, Plant, and Equipment	3.7Cr	1.34TCr	58Cr	196.4Cr	1.46TCr
Cash Acquisitions	-23Cr	-121.7Cr	-	-	-26Cr
Divestitures	-	-	521Cr	-	-
Sale (Purchase) of Intangible assets	-1.9TCr	-1.14TCr	-1.2TCr	-1.05TCr	-1.1TCr
Investment in Marketable and Equity Securities, Total	20Cr	10L	14Cr	8.7Cr	-
Other Investing Activities, Total	126.5Cr	-61Cr	591.1Cr	-254.9Cr	-147.6Cr
Cash from Investing	-3.69TCr	-2.88TCr	-2.27TCr	-2.53TCr	-1.01TCr
Short Term Debt Issued, Total	-	-	3.12TCr	-	2.83TCr
Long-Term Debt Issued, Total	3.49TCr	4.49TCr	-	4.98TCr	-
Total Debt Issued	3.49TCr	4.49TCr	3.12TCr	4.98TCr	2.83TCr
Short Term Debt Repaid, Total	-	-	-	-656.9Cr	-
Long-Term Debt Repaid, Total	-3.5TCr	-4TCr	-2.9Cr	-1TCr	-90L
Total Debt Repaid	-3.5TCr	-4TCr	-2.9Cr	-1.66TCr	-90L
Repurchase of Common Stock	-	-	-	-	-3.01TCr
Common Dividends Paid	-4.59TCr	-4.59TCr	-4.59TCr	-4.59TCr	-4.55TCr
Common & Preferred Stock Dividends Paid	-4.59TCr	-4.59TCr	-4.59TCr	-4.59TCr	-4.55TCr
Other Financing Activities, Total	-995.8Cr	-796.3Cr	-980.1Cr	-1.01TCr	-1.04TCr
Cash from Financing	-5.59TCr	-4.9TCr	-2.45TCr	-2.27TCr	-5.78TCr
Foreign Exchange Rate Adjustments	1.34TCr	2.11TCr	673.5Cr	2.94TCr	-132.7Cr
Miscellaneous Cash Flow Adjustments	10L	-10L	-	10L	-10L
Net Change in Cash	-550.3Cr	6.09TCr	-4.23TCr	3.73TCr	-3.91TCr
Supplemental Items
Cash Interest Paid	102.6Cr	128.6Cr	148.4Cr	155.8Cr	254.6Cr
Cash Income Tax Paid (Refund)	1.68TCr	710.9Cr	2.26TCr	920.5Cr	1.78TCr
Levered Free Cash Flow	2.73TCr	5.95TCr	-5.11TCr	-41Cr	560.55Cr
Unlevered Free Cash Flow	2.8TCr	6.04TCr	-5TCr	77Cr	732.74Cr
Change In Net Working Capital	338.2Cr	-3.59TCr	7.95TCr	4.14TCr	3.9TCr
Net Debt Issued / Repaid	-8.2Cr	487.4Cr	3.12TCr	3.33TCr	2.83TCr

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	3.09	2.28	1.92	2.07	2.12
Return on Total Capital	4.13	3.15	2.65	2.75	2.79
Return On Equity %	5.94	6.1	7.13	5.09	5.45
Return on Common Equity	6.1	6.61	7.16	5.06	5.41
Margin Analysis
Gross Profit Margin %	75.03	76.88	76.11	79.06	78.62
SG&A Margin	42.2	47.19	46.77	49.08	50.24
EBITDA Margin %	13.86	10.69	10.53	11.25	11.02
EBITA Margin %	8.24	5.61	5.16	5.94	5.96
EBIT Margin %	8.24	5.61	5.16	5.94	5.96
Income From Continuing Operations Margin %	6.58	6.05	7.64	5.9	6.09
Net Income Margin %	6.52	6.34	7.45	5.72	5.88
Net Avail. For Common Margin %	6.52	6.34	7.45	5.72	5.88
Normalized Net Income Margin	5.02	3.69	3.14	4.25	3.9
Levered Free Cash Flow Margin	4.23	7.87	-6.86	-0.05	0.71
Unlevered Free Cash Flow Margin	4.34	7.98	-6.72	0.1	0.93
Asset Turnover
Asset Turnover	0.6	0.65	0.59	0.56	0.57
Fixed Assets Turnover	4.23	4.57	4.42	4.47	4.89
Receivables Turnover (Average Receivables)	3.8	4.11	3.77	3.67	3.61
Inventory Turnover (Average Inventory)	2.14	1.9	1.49	0.99	0.86
Short Term Liquidity
Current Ratio	2.02	2.04	2.08	2.37	1.95
Quick Ratio	1.6	1.65	1.52	1.71	1.3
Operating Cash Flow to Current Liabilities	0.29	0.38	-0.01	0.18	0.08
Days Sales Outstanding (Average Receivables)	96.15	88.87	96.89	99.79	101.08
Days Outstanding Inventory (Average Inventory)	170.67	192.2	245.7	371.19	422.24
Average Days Payable Outstanding	173.14	195.93	162.23	153.56	142.33
Cash Conversion Cycle (Average Days)	93.68	85.14	180.37	317.41	380.99
Long Term Solvency
Total Debt/Equity	12.35	12.3	15.33	17.73	21.65
Total Debt / Total Capital	10.99	10.95	13.29	15.06	17.8
LT Debt/Equity	6.86	12.3	10.32	14.99	11.53
Long-Term Debt / Total Capital	6.1	10.95	8.95	12.73	9.48
Total Liabilities / Total Assets	33.22	37.75	34.89	35.5	37.54
EBIT / Interest Expense	45.88	29.7	23.18	23.4	17.09
EBITDA / Interest Expense	77.17	56.57	47.3	44.31	31.57
(EBITDA - Capex) / Interest Expense	60.66	36.25	33.68	36.71	27.24
Total Debt / EBITDA	1	1.17	1.61	1.91	2.16
Net Debt / EBITDA	-1.77	-2.66	-1.8	-1.74	-0.9
Total Debt / (EBITDA - Capex)	1.28	1.83	2.26	2.3	2.5
Net Debt / (EBITDA - Capex)	-2.26	-4.15	-2.53	-2.1	-1.04
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-7.14	17.07	-1.56	-0.36	6.42
Gross Profit, 1 Yr. Growth %	-6.79	19.97	-2.55	3.5	5.83
EBITDA, 1 Yr. Growth %	-42.76	-9.7	-2.99	6.46	4.19
EBITA, 1 Yr. Growth %	-56.62	-20.26	-9.43	14.7	6.77
EBIT, 1 Yr. Growth %	-56.62	-20.26	-9.43	14.7	6.77
Earnings From Cont. Operations, 1 Yr. Growth %	-65.31	7.61	24.32	-22.97	9.76
Net Income, 1 Yr. Growth %	-65.41	13.85	15.59	-23.5	9.49
Normalized Net Income, 1 Yr. Growth %	-57.59	-13.99	-16.32	35.09	-2.31
Diluted EPS Before Extra, 1 Yr. Growth %	-65.42	13.85	15.58	-23.51	10.76
Accounts Receivable, 1 Yr. Growth %	-10.95	29.72	-9.95	16	1.3
Inventory, 1 Yr. Growth %	29.49	16.32	41.82	24.38	23.62
Net Property, Plant and Equip., 1 Yr. Growth %	11.27	5.59	-1.94	-1.04	-4.13
Total Assets, 1 Yr. Growth %	2.62	13.7	1.94	10.33	-0.52
Tangible Book Value, 1 Yr. Growth %	4.81	9.19	8.73	10.33	-3.8
Common Equity, 1 Yr. Growth %	3.69	6.49	6.83	9.46	-3.91
Cash From Operations, 1 Yr. Growth %	-28.15	59.22	-101.51	-3.26T	-46.21
Capital Expenditures, 1 Yr. Growth %	25.45	51.61	-22.23	-36.57	-16.67
Levered Free Cash Flow, 1 Yr. Growth %	-43.3	117.84	-185.83	-99.2	-1.48T
Unlevered Free Cash Flow, 1 Yr. Growth %	-42.64	115.39	-182.84	-101.54	850.22
Dividend Per Share, 1 Yr. Growth %	0	0	0	0	0
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	0.24	4.27	7.35	-0.96	2.98
Gross Profit, 2 Yr. CAGR %	2.83	5.75	8.12	0.43	4.66
EBITDA, 2 Yr. CAGR %	-10.93	-28.11	-6.41	1.63	5.32
EBITA, 2 Yr. CAGR %	-21.33	-41.19	-15.02	1.93	10.67
EBIT, 2 Yr. CAGR %	-21.33	-41.19	-15.02	1.93	10.67
Earnings From Cont. Operations, 2 Yr. CAGR %	-20.06	-38.9	15.67	-2.14	-8.05
Net Income, 2 Yr. CAGR %	-18.48	-37.25	14.72	-5.96	-8.48
Normalized Net Income, 2 Yr. CAGR %	-21.39	-39.6	-15.16	6.32	14.88
Diluted EPS Before Extra, 2 Yr. CAGR %	-18.49	-37.25	14.71	-5.98	-7.96
Accounts Receivable, 2 Yr. CAGR %	1.16	7.48	8.08	2.2	8.4
Inventory, 2 Yr. CAGR %	11.97	22.73	28.44	32.82	24
Net Property, Plant and Equip., 2 Yr. CAGR %	23.7	8.39	1.76	-1.49	-2.6
Total Assets, 2 Yr. CAGR %	0.86	8.02	7.66	6.05	4.76
Tangible Book Value, 2 Yr. CAGR %	8.7	6.98	8.96	9.53	3.02
Common Equity, 2 Yr. CAGR %	5.81	5.08	6.66	8.14	2.56
Cash From Operations, 2 Yr. CAGR %	-15.62	6.96	-84.51	-30.99	312.26
Capital Expenditures, 2 Yr. CAGR %	2.66	37.91	8.58	-29.76	-27.3
Levered Free Cash Flow, 2 Yr. CAGR %	-28.45	11.14	36.74	-91.74	-66.87
Unlevered Free Cash Flow, 2 Yr. CAGR %	-28.06	11.16	33.58	-88.7	-61.73
Dividend Per Share, 2 Yr. CAGR %	3.28	0	0	0	0
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	2.49	5.56	2.28	4.72	1.44
Gross Profit, 3 Yr. CAGR %	6.71	8.25	2.9	6.56	2.2
EBITDA, 3 Yr. CAGR %	-4.3	-10.52	-20.55	-2.3	2.47
EBITA, 3 Yr. CAGR %	-11.18	-20.97	-32.08	-6.08	3.52
EBIT, 3 Yr. CAGR %	-11.18	-20.97	-32.08	-6.08	3.52
Earnings From Cont. Operations, 3 Yr. CAGR %	-7.92	-11.74	-22.58	1.01	1.68
Net Income, 3 Yr. CAGR %	-6.69	-8.88	-23.07	0.23	-1.07
Normalized Net Income, 3 Yr. CAGR %	-10.14	-18.99	-32.67	-0.93	3.36
Diluted EPS Before Extra, 3 Yr. CAGR %	-6.72	-8.89	-23.08	0.22	-0.7
Accounts Receivable, 3 Yr. CAGR %	1.91	9.91	1.32	10.66	1.9
Inventory, 3 Yr. CAGR %	1.7	13.4	28.79	27.07	29.68
Net Property, Plant and Equip., 3 Yr. CAGR %	16.02	17.34	4.83	0.81	-2.38
Total Assets, 3 Yr. CAGR %	1.29	4.97	5.95	8.54	3.81
Tangible Book Value, 3 Yr. CAGR %	9.59	8.86	7.56	9.41	4.89
Common Equity, 3 Yr. CAGR %	5.81	6.03	5.66	7.58	3.96
Cash From Operations, 3 Yr. CAGR %	-20.98	4.27	-74.17	-8.82	-36.49
Capital Expenditures, 3 Yr. CAGR %	22.18	16.91	13.94	-9.23	-25.65
Levered Free Cash Flow, 3 Yr. CAGR %	-40.66	3.7	1.97	-75.4	-54.5
Unlevered Free Cash Flow, 3 Yr. CAGR %	-40.41	3.69	0.78	-69.81	-50.49
Dividend Per Share, 3 Yr. CAGR %	2.17	2.17	0	0	0
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	3.35	7	4.41	2.9	2.56
Gross Profit, 5 Yr. CAGR %	6.52	11.12	7.28	5.05	3.6
EBITDA, 5 Yr. CAGR %	4.28	0.75	-5.15	-5.85	-11.07
EBITA, 5 Yr. CAGR %	6.67	-3.75	-12.74	-12.51	-17.44
EBIT, 5 Yr. CAGR %	6.67	-3.75	-12.74	-12.51	-17.44
Earnings From Cont. Operations, 5 Yr. CAGR %	-5.05	1.59	0.87	-8.01	-17.06
Net Income, 5 Yr. CAGR %	-5.17	4.03	1.35	-7.72	-17.54
Normalized Net Income, 5 Yr. CAGR %	8.93	0.15	-12.18	-9.68	-16.63
Diluted EPS Before Extra, 5 Yr. CAGR %	-5.19	4.01	1.33	-7.73	-17.36
Accounts Receivable, 5 Yr. CAGR %	1.66	6.12	4.33	6.76	4.09
Inventory, 5 Yr. CAGR %	2.93	3.62	11.65	20.8	26.85
Net Property, Plant and Equip., 5 Yr. CAGR %	9.01	10.41	10.09	9.41	1.79
Total Assets, 5 Yr. CAGR %	2.28	3.75	3.79	5.4	5.48
Tangible Book Value, 5 Yr. CAGR %	7.49	9.14	9.34	9.13	5.72
Common Equity, 5 Yr. CAGR %	4.16	5.08	6.15	6.87	4.41
Cash From Operations, 5 Yr. CAGR %	-5.03	9.16	-58.82	-11.6	-21.77
Capital Expenditures, 5 Yr. CAGR %	22.95	29.98	16.55	-4.65	-4.8
Levered Free Cash Flow, 5 Yr. CAGR %	7.02	13.04	-17.14	-62.3	-34.96
Unlevered Free Cash Flow, 5 Yr. CAGR %	5.36	12.21	-17.7	-57.28	-31.58
Dividend Per Share, 5 Yr. CAGR %	1.3	1.3	1.3	1.3	0